<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489086</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000551655</org_study_id>
    <secondary_id>R01CA109584</secondary_id>
    <nct_id>NCT00489086</nct_id>
    <nct_alias>NCT00500643</nct_alias>
  </id_info>
  <brief_title>Topical Tazarotene in Treating Patients With Basal Cell Skin Cancer and Basal Cell Nevus Syndrome on the Face</brief_title>
  <official_title>A Phase II Single Arm Open-Label Clinical Trial of Chemotherapy of BCC's With Tazarotene 0.1% in Subjects With Basal Cell Nevus Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCSF Benioff Children's Hospital Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>UCSF Benioff Children's Hospital Oakland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as tazarotene, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying topical tazarotene to see how well it works in&#xD;
      treating patients with basal cell skin cancer and basal cell nevus syndrome on the face.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether topical tazarotene, administered over a period of 18 months as a&#xD;
           chemopreventive agent, reduces the incidence of basal cell carcinomas (BCCs) on treated&#xD;
           skin in patients with basal cell nevus syndrome (BCNS).&#xD;
&#xD;
        -  Expand and refine chemopreventive strategies in patients with BCNS who are at high risk&#xD;
           for the development of BCCs.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients apply topical tazarotene cream to the face once daily for 18 months in the absence&#xD;
      of unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>36 months</time_frame>
    <description>The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's &quot;target&quot; lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Lesion Clearance</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Duration of Complete Response</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response at Treated Lesions</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Neoplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Tazarotene Cream</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Open label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tazarotene</intervention_name>
    <description>Tazarotene is a member of the acetylenic class of retinoids.</description>
    <arm_group_label>Tazarotene Cream</arm_group_label>
    <other_name>tazorac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        List of Inclusion Criteria:&#xD;
&#xD;
          1. Study subjects must have at least one basal cell carcinoma â‰¥ 3mm in diameter (target&#xD;
             lesion) on any area of the skin except the face, chest, and back (and not impinging on&#xD;
             vital sites) diagnosed clinically by a Study Investigator at the baseline visit.&#xD;
&#xD;
          2. Study subjects must meet diagnostic criteria for basal cell nevus syndrome including&#xD;
             major criterion #1 plus one additional major criterion or two of the minor criteria&#xD;
             outlined in Table I. A first degree relative would satisfy BCNS diagnostic criteria&#xD;
             with any two major criteria or any single major plus two minor criteria.&#xD;
&#xD;
        Table I. BCNS Diagnostic Criteria&#xD;
&#xD;
        Major criteria&#xD;
&#xD;
          1. More than 2 BCCs or one under the age of 20 years&#xD;
&#xD;
          2. Odontogenic keratocysts of the jaw proven by histology&#xD;
&#xD;
          3. Three or more palmar and/or plantar pits&#xD;
&#xD;
          4. Bilamellar calcification of the falx cerebri (if less than 20 years old)&#xD;
&#xD;
          5. Fused, bifid, or markedly splayed ribs.&#xD;
&#xD;
          6. First degree relative with basal cell nevus syndrome (BCNS)&#xD;
&#xD;
          7. PTCH1 gene mutation in normal tissue*&#xD;
&#xD;
        Minor criteria&#xD;
&#xD;
          1. Macrocephaly determined after adjustment for height&#xD;
&#xD;
          2. Congenital malformations: cleft lip or palate, frontal bossing, &quot;coarse face.&quot;&#xD;
&#xD;
          3. Skeletal abnormalities: Sprengel deformity, marked pectus deformity&#xD;
&#xD;
          4. Radiological abnormalities: bridging of the sella turcica, vertebral anomalies such as&#xD;
             hemivertebrae, fusion or elongation of the vertebral bodies.&#xD;
&#xD;
          5. Ovarian fibroma&#xD;
&#xD;
          6. Medulloblastoma&#xD;
&#xD;
        3.The subject is from 18-75 years of age, inclusive.&#xD;
&#xD;
        4. If the subject is female and of child-bearing potential (women are considered not of&#xD;
        childbearing potential if they are at least 2 years post-menopausal and/or surgically&#xD;
        sterile), she:&#xD;
&#xD;
        i. has been using adequate contraception (abstinence, IUD, birth control pills, or&#xD;
        spermicidal gel with diaphragm or condom) since her last menses and will use adequate&#xD;
        contraception during the study, and ii. is not lactating, and iii. has documented one&#xD;
        negative serum pregnancy test within 14 days prior to study entry.&#xD;
&#xD;
        5. The subject is willing to abstain from application of non-study topical medications to&#xD;
        the skin of the face for the duration of the study, including prescription and over the&#xD;
        counter preparations.&#xD;
&#xD;
        6. The subject is willing not to have targeted BCCs treated by their PSCP unless the BCCs&#xD;
        are documented by Study Investigators, preferably on two separate visits, except when the&#xD;
        PSCP believes that delay in treatment potentially might compromise the health of the&#xD;
        subject.&#xD;
&#xD;
        List of Exclusion Criteria:&#xD;
&#xD;
          1. The subject has used topical or systemic therapies that might interfere with the&#xD;
             evaluation of the study medication during the study.&#xD;
&#xD;
          2. The subject has a history of hypersensitivity to any of the ingredients in the study&#xD;
             medication formulations.&#xD;
&#xD;
          3. The subject is unable to return for follow-up tests.&#xD;
&#xD;
          4. The subject has uncontrolled systemic disease, including known HIV positive patients.&#xD;
&#xD;
          5. The subject has a history of other skin conditions or significant illness that would&#xD;
             interfere with evaluation of the study medication.&#xD;
&#xD;
          6. Any condition or situation which in the Investigator's opinion may put the subject at&#xD;
             significant risk, could confound the study results, or could interfere significantly&#xD;
             with the subject's participation in the study.&#xD;
&#xD;
          7. The subject has a history of invasive cancer within the past five years excluding&#xD;
             non-melanoma skin cancer, Stage I cervical cancer, or CLL Stage 0.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ervin Epstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Benioff Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David R. Bickers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herbert Irving Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Tang JY, Chiou AS, Mackay-Wiggan JM, Aszterbaum M, Chanana AM, Lee W, Lindgren JA, Raphael MA, Thompson BJ, Bickers DR, Epstein EH Jr. Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndrome. Cancer Prev Res (Phila). 2014 Mar;7(3):292-9. doi: 10.1158/1940-6207.CAPR-13-0305. Epub 2014 Jan 17.</citation>
    <PMID>24441673</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <results_first_submitted>July 31, 2013</results_first_submitted>
  <results_first_submitted_qc>January 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2016</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nevoid basal cell carcinoma syndrome</keyword>
  <keyword>basal cell carcinoma of the skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Basal Cell Nevus Syndrome</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazarotene</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tazarotene Cream</title>
          <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 18 Months</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tazarotene Cream</title>
          <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Complete Response Rate</title>
        <description>The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's &quot;target&quot; lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less.</description>
        <time_frame>36 months</time_frame>
        <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
        <group_list>
          <group group_id="O1">
            <title>Tazarotene Cream</title>
            <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response Rate</title>
          <description>The primary endpoint used to evaluate tazarotene efficacy for BCC chemotherapy was the complete response (CR) rate, defined as the complete visible disappearance of a patient's &quot;target&quot; lesion during the the 18 months of tazarotene application and its failure to recur during the ensuing 18-months. We defined surgical removal of a target lesion as a treatment failure. The primary endpoint was assessed based on intention to treat analysis such that any subject who underwent the baseline evaluation and applied at least 1 dose of tazarotene was included in the analysis. Drop-outs were considered non-responders. A priori treatment success for tazarotene was defined as a CR rate of at least 50%, and treatment failure was defined as a CR rate of 25% or less.</description>
          <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Lesion Clearance</title>
        <time_frame>36 months</time_frame>
        <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
        <group_list>
          <group group_id="O1">
            <title>Tazarotene Cream</title>
            <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Lesion Clearance</title>
          <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The PI has left the institution and the only access to the data is from the publication. The access to this specific data cannot be confirmed and is not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <time_frame>36 months</time_frame>
        <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
        <group_list>
          <group group_id="O1">
            <title>Tazarotene Cream</title>
            <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The PI has left the institution and the only access to the data is from the publication. The access to this specific data cannot be confirmed and is not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Duration of Complete Response</title>
        <time_frame>36 months</time_frame>
        <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
        <group_list>
          <group group_id="O1">
            <title>Tazarotene Cream</title>
            <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Duration of Complete Response</title>
          <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The PI has left the institution and the only access to the data is from the publication. The access to this specific data cannot be confirmed and is not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response at Treated Lesions</title>
        <time_frame>36 months</time_frame>
        <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
        <group_list>
          <group group_id="O1">
            <title>Tazarotene Cream</title>
            <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response at Treated Lesions</title>
          <population>N=2 participants excluded from analysis: N=1 due to revised BCNS diagnosis and N=1 because unable to confirm administration of at least one dose of tazarotene.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The PI has left the institution and the only access to the data is from the publication. The access to this specific data cannot be confirmed and is not available to be reported.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>36 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tazarotene Cream</title>
          <description>This is a 36 month, multi-center, single arm, open label clinical study design</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>cellulitis and maxillary sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>prostate cancer diagnosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>irritation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>dryness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>itching</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>peeling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ervin H Epstein Jr., MD</name_or_title>
      <organization>Children's Hospital of Oakland Research Institute, Oakland</organization>
      <phone>510-450-5688</phone>
      <email>eepstein@chori.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

